NCT07029581Phase 2Recruiting

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2028-02Estimated
Enrollment · participants180Estimated
Source updated2026-08-24Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.